SEATTLE– TwinStrand Biosciences, Inc., the pioneer and developer of duplex sequencing, today announced the appointment of Goran Pljevaljcic, Ph.D. as Chief Commercial Officer. Dr. Pljevaljcic brings a successful track-record of commercial leadership in the genomics industry to TwinStrand, including experience building and managing clinical and research products through all stages of commercialization.
“TwinStrand is pleased to welcome Goran to the team. His experience further solidifies our management team and brings capabilities that will be invaluable as we continue to expand our commercial portfolio of high-resolution duplex sequencing offerings,” said TwinStrand CEO Jesse Salk, M.D., Ph.D. “Goran brings demonstrated commercial expertise that will support the acceleration of our efforts to broadly deliver the unprecedented accuracy of duplex sequencing technology to applications in clinical medicine and the life sciences.”
Dr. Pljevaljcic is a seasoned commercial leader with more than two decades of experience in the life sciences, the last nine years of which he focused on leading commercial teams in the genomics industry. He joined TwinStrand from Bionano Genomics (NASDAQ: BNGO), a public genomics company providing solutions for structural genome analysis with applications in cancer and genetic disease. Dr. Pljevaljcic has held various positions of increasing responsibility including director positions of business development, of strategy and corporate development, vice president of global commercial operations, and most recently served as vice president of sales and support. Prior to that, he marketed and out-licensed IP from the Scripps Research Institute through their tech transfer office and consulted for private biotech companies. He holds a Ph.D. in chemistry from the University of Dortmund/Max Planck Institute of Molecular Physiology in Germany.
“TwinStrand’s pioneering duplex sequencing approach is a powerful and elegant solution that extends the value of next-generation sequencing to enable the illumination of important low frequency variants that are not currently detectable by other methods,” said Dr. Pljevaljcic. “It is an honor to join Jesse and the entire TwinStrand team and I look forward to advancing our mission to improve human health and accelerate scientific discovery.”
